Table 2 Patient characteristics.

From: Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

 

High-Dose Regimen* (n = 96)

Low-Dose Regimen† (n = 93)

Vehicle (n = 98)

Total (N = 287)

Age‡

 Mean, years (SD)

9.2 (3.4)

9.1 (3.2)

8.7 (2.9)

9.0 (3.2)

 4–11 years, n (%)

73 (76.0)

71 (76.3)

79 (80.6)

223 (77.7)

 12–18 years, n (%)

22 (22.9)

22 (23.7)

19 (19.4)

63 (22.0)

Sex, n (%)

 Male

78 (81.3)

75 (80.6)

75 (76.5)

228 (79.4)

Form of VKC, n (%)

 Limbal

8 (8.3)

2 (2.2)

7 (7.1)

17 (5.9)

 Tarsal

23 (24.0)

20 (21.5)

29 (29.6)

72 (25.1)

 Both

65 (67.7)

71 (76.3)

62 (63.3)

198 (69.0)

Type of VKC, n (%)

 Seasonal

38 (39.6)

35 (37.6)

30 (30.6)

103 (35.9)

 Perennial

58 (60.4)

58 (62.4)

68 (69.4)

184 (64.1)

Mean time since diagnosis, years (SD)

3.8 (2.6)

3.5 (2.4)

3.3 (2.4)

3.5 (2.5)

CFS at baseline, n (%)

 Grade ≤2

15 (15.6)

10 (10.8)

11 (11.2)

36 (12.5)

 Grade 3

10 (10.4)

14 (15.1)

14 (14.3)

38 (13.2)

 Grade 4

54 (56.3)

59 (63.4)

63 (64.3)

176 (61.3)

 Grade 5

17 (17.7)

10 (10.8)

10 (10.2)

37 (12.9)

  1. BID twice daily, CFS corneal fluorescein staining, CsA CE cyclosporine A cationic ophthalmic emulsion, QID 4 times daily, SD standard deviation, VKC vernal keratoconjunctivitis.
  2. *CsA CE 0.1% QID arms from both trials.
  3. †CsA CE 0.05% QID arm from NOVATIVE and CsA CE 0.1% BID data from VEKTIS.
  4. ‡Day and month of birth were missing for 1 patient in the NOVATIVE study; they were replaced by the 1st of July for the calculation of age (11 years).
Back to article page